53 related articles for article (PubMed ID: 15902295)
1. Risk Factors for Childhood Leukemia: Radiation and Beyond.
Schmidt JA; Hornhardt S; Erdmann F; Sánchez-García I; Fischer U; Schüz J; Ziegelberger G
Front Public Health; 2021; 9():805757. PubMed ID: 35004601
[TBL] [Abstract][Full Text] [Related]
2. Abstracts from the Seventh International Workshop on Immune-deficient Animals.
Ilar News; 1992 Jan; 34(1-2):S1-S36. PubMed ID: 34191868
[No Abstract] [Full Text] [Related]
3. Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
Larsen RH; Utke Rank C; Grell K; Nørgaard Møller L; Malthe Overgaard U; Kampmann P; Nersting J; Degn M; Nygaard Nielsen S; Holst H; Klug Albertsen B; Skov Wehner P; Thude Callesen M; Kanerva J; Leth Frandsen T; Als-Nielsen B; Lyngsie Hjalgrim L; Schmiegelow K
Haematologica; 2021 Nov; 106(11):2824-2833. PubMed ID: 34047177
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
5. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
6. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.
Moriyama T; Nishii R; Perez-Andreu V; Yang W; Klussmann FA; Zhao X; Lin TN; Hoshitsuki K; Nersting J; Kihira K; Hofmann U; Komada Y; Kato M; McCorkle R; Li L; Koh K; Najera CR; Kham SK; Isobe T; Chen Z; Chiew EK; Bhojwani D; Jeffries C; Lu Y; Schwab M; Inaba H; Pui CH; Relling MV; Manabe A; Hori H; Schmiegelow K; Yeoh AE; Evans WE; Yang JJ
Nat Genet; 2016 Apr; 48(4):367-73. PubMed ID: 26878724
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose Optimization.
Jayachandran D; Laínez-Aguirre J; Rundell A; Vik T; Hannemann R; Reklaitis G; Ramkrishna D
PLoS One; 2015; 10(7):e0133244. PubMed ID: 26226448
[TBL] [Abstract][Full Text] [Related]
8. Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.
Jayachandran D; Rundell AE; Hannemann RE; Vik TA; Ramkrishna D
PLoS One; 2014; 9(10):e109623. PubMed ID: 25310465
[TBL] [Abstract][Full Text] [Related]
9. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
12. The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009.
Biondi A; Baruchel A; Hunger S; Masera G; Schmiegelow K; Schrappe M; Pui CH
Leukemia; 2009 Dec; 23(12):2318-24. PubMed ID: 19890375
[TBL] [Abstract][Full Text] [Related]
13. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
[No Abstract] [Full Text] [Related]
14. The U.S. trials in adult acute lymphoblastic leukemia.
Larson RA
Ann Hematol; 2004; 83 Suppl 1():S127-8. PubMed ID: 15124704
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Cunningham L; Aplenc R
Expert Opin Pharmacother; 2007 Oct; 8(15):2519-31. PubMed ID: 17931087
[TBL] [Abstract][Full Text] [Related]
16. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005.
Aricó M; Baruchel A; Bertrand Y; Biondi A; Conter V; Eden T; Gadner H; Gaynon P; Horibe K; Hunger SP; Janka-Schaub G; Masera G; Nachman J; Pieters R; Schrappe M; Schmiegelow K; Valsecchi MG; Pui CH
Leukemia; 2005 Jul; 19(7):1145-52. PubMed ID: 15902295
[TBL] [Abstract][Full Text] [Related]
17. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005.
Gadner H; Masera G; Schrappe M; Eden T; Benoit Y; Harrison C; Nachman J; Pui CH
Leukemia; 2006 Jan; 20(1):9-17. PubMed ID: 16281070
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
